Molecular biomarkers to individualise treatment: Assessing the evidence

Medical Journal of Australia

Volumn 190, Issue 11, 2009, Pages 631-636

  Lee, Chee K ^a   Lord, Sarah J ^a,b   Coates, Alan S ^b,c   Simes, R John ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c International Breast Cancer Study Group   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; PANITUMUMAB; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

ANTICOAGULANT THERAPY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DNA SEQUENCE; EPIGENETICS; ESTROGEN THERAPY; EVALUATION RESEARCH; EVIDENCE BASED PRACTICE; HEART ATRIUM FIBRILLATION; HIGH THROUGHPUT SCREENING; HUMAN; INDIVIDUALISED TREATMENT; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; MEDICAL INFORMATION; ONCOGENE K RAS; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STROKE; SURVIVAL; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; BREAST TUMOR; FEMALE; HOSPITAL INFORMATION SYSTEM; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PREDICTION AND FORECASTING; STANDARD;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 68349115159     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02592.x     Document Type: Review

References (25)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
2. Lord S, Lee C, Simes RJ. The role of prognostic and predictive markers in cancer. Cancer Forum 2008; 32 (3): 139-142.
3. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ 1995; 311: 1356-1359.
4. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456-1466.
5. Pepe MS. Evaluating technologies for classification and prediction in medicine. Stat Med 2005; 24: 3687-3696.
6. Ransohof DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J Clin Epidemiol 2007; 60: 1205-1219.
7. Rose G, Shipley M. Plasma cholesterol concentration and death from coronary heart disease: 10 year results of the Whitehall study. Br Med J (Clin Res Ed) 1986; 293: 306-307. (Pubitemid 16037549)
8. The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chronic Dis 1978; 31: 201-306.
9. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
10. Bonetti M, Gelber R. A graphical method to assess treatment - covariate interactions using the Cox model on subsets of the data. Stat Med 2000; 19: 2595-2609.
11. Royston P, Sauerbrei W. A new approach to modeling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 2004; 23: 2509-2525. (Pubitemid 39149264)
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
13. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746. (Pubitemid 26329660)
14. Fisher B, Redmond C, Fisher ER, Caplan R. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988; 6: 1076-1087.
15. Bossuyt PM, Lijmer JG, Mol BW. Randomised comparisons of medical tests: sometimes invalid, not always efficient. Lancet 2000; 356: 1844-1847.
16. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005; 23: 2020-2027. (Pubitemid 46211382)
17. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004; 10: 6759-6763. (Pubitemid 39383023)
18. Salmon DJ, Leyland-Jone B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 positive metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)
19. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26: 721-728. (Pubitemid 351264384)
20. International Breast Cancer Study Group (IBCSG). Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph nodenegative breast cancer: a randomized trial. J Natl Cancer Inst 2002; 94: 1054-1065.
21. Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006; 3: 540-551. (Pubitemid 44781724)
22. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
23. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145. (Pubitemid 350003059)
24. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008; 358: 1409-1411. (Pubitemid 351468442)
25. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.